ARYx Therapeutics, Inc.
ARYX · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Market Cap | $88 | $55 | $73 | $8 |
| - Cash | $7 | $36 | $55 | $19 |
| + Debt | $12 | $15 | $7 | $10 |
| Enterprise Value | $92 | $34 | $24 | -$1 |
| Revenue | $0 | $20 | $4 | $5 |
| % Growth | -100% | 374.4% | -12.3% | – |
| Gross Profit | $0 | $19 | $4 | $3 |
| % Margin | – | 98.8% | 93.7% | 55.3% |
| EBITDA | -$30 | -$29 | -$28 | -$27 |
| % Margin | – | -148.7% | -662.9% | -577.5% |
| Net Income | -$33 | -$31 | -$28 | -$27 |
| % Margin | – | -158.3% | -662.8% | -576.7% |
| EPS Diluted | -1.21 | -1.65 | -2.93 | -26.84 |
| % Growth | 26.7% | 43.7% | 89.1% | – |
| Operating Cash Flow | -$35 | -$45 | -$28 | -$4 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$1 |
| Free Cash Flow | -$35 | -$46 | -$28 | -$5 |